AMG trade ideas
$AMGN LONG IDEA$AMGN is one of my favorite bio tech stocks as it has solidified its place as a winner over the years. They had a bit of a slowdown and consolidation over the past few years as they didn't have as much involvement with COVID, but certainly didn't lose too much value.
Watch for a 4hr close above $241.50 to send us back to $260+ over next few weeks.
$AMGN with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $AMGN after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
Amgn analise wyckoffon this entry we have a distribution phase now we see a support point which confirmed the testing of the climactic movement
W PatternsAs a rule, when I see a crooked W, I steer clear and watch it if it is a security I want. The impulse/long leg/is to the downside whereas a bullish crooked M pattern, the impulse leg is up. We are all different.
Crooked Ws are not always bearish, but it just gets too complicated for this post so I will stop there. For the most part, a W is bearish.
I have noted a W will pull to the middle, or the hump, or point in the middle of the W. I marked it with a green X.
Does this always happen? NO. Can it go further than this point or not as far? YES. Just a guide for me, and we are all different.
Does the same exact thing happen twice in the market on a regular basis? NO LOL
Often a Double Bottom will have a W associated with it. I often wait for price to come back to this point and reassess if I am not already in the security when I see it. You can do fib levels to figure out which bearish harmonic pattern the W represents if you wish to hang on to the last leg up of that W, then sell and catch it again when it hits another entry level. Ws are usually bearish but if you know your patterns, it is possible to go long on the last leg up of the W.
No recommendation
Tomorrow is another day (o:
ABC BullishPossible stop under C.
No recommendation.
Short percent is 2.14%.
Earnings due again on 5-18 BMO.
W not so attractive but have noted that securities often pull to the middle hump of the W and this one is very close. With double bottoms often there is a W associated with the double bottom. Ws can be bearish. The tail of a red long legged doji candle did hit the 2nd
leg of the W.
AMGN Long Term LongTop pharma pick right now other than BMY. P/E 13.11 with forecasted 6-7% earnings growth and an EPS yield of 7.62%.
Historic Norm P/E 18.89
^ 10 Y = 14.50
^ 5 Y = 14.25
3.49% Div payer.
Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Bearish on Amgen. AMGNImmediate targets 211, 200,186. Invalidation at 279.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
AMGN ShortCommodity Channel Index (CCI)
Jan 26 Daily
Short-Term Bearish
Volume 2,799,706
Close Price 222.54
Pattern Duration 1 day
Triple Moving Average Crossover (4-day 9-day 18-day)
Jan 27 Daily
Short-Term Bearish
Volume 2,492,054
Close Price 224.00
Pattern Duration 1 day
Commodity Channel Index (CCI)
Jan 27 Daily
Other
Volume 2,492,054
Close Price 224.00
Pattern Duration 1 day
AMGN has a nice setupAMGN looks ready to rip. Bullish crossover on the Stochastic, Super Trend is green and price closed above the 200 EMA. Looking for $230+ this week.
AMGN_Continue the correction processLocated close to dynamic resistance.
Be careful on the BUY side.
The RSI has also reached the buy saturation zone.
BUY after breaking the dynamic resistance and stabilizing it high.
Buy $AMGN - NRPicks 19 NovAmgen Inc. discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. It has agreements with Novartis, Bayer, among others.
Revenue TTM 25.7B
Net Income TTM 5.6B
EBITDA TTM 12.1B
EBITDA margin TTM 47.1%.
Debt/EBITDA TTM 3.05x
$AMGN bouncing off MT support (4/5)Conviction: 4/5
there may be near-term pullback for better entry at support
General Thesis
bounce from medium-term resistance (2017)
although a bit of indecision around resistance line
Weekly RSI showing good bounce near historical support
Growth
Margins high but declined in 2021
growth is low but around 50th percentile compared to self
Value
P/FCF is high: about 80th percentile
P/S is below average: about 35th percentile
Fundamentals/Balance Sheet
debt/asset ratio good: below 1
quick ratio good: above 1
Potential Risks
expensive market...
AMGEN a safe buy?AMGEN INC seems to be a solid buy for a +30% move to the upside within 12 month. So not a super exciting play. But never the less I'll share it with you. We had a productive EWT a-b-c like movement to the downside as a correction. We have bounced on the multi year (since 2017) support trendline (green) and should see another test of the ATH within next 12 months. Stop loss at the green support. Or maybe a false break to test the fib 38.2? Anyway should be decent risk reeward in this trade.
$AMGN with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $AMGN after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 60%.
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
Amgen Announces Positive Top-Line Results From Otezla® (apremilaAMGN: Amgen Inc.
2021-12-01 16:00:00
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Buy $AMGN - NRPicks 10 SetAmgen Inc. discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience. It has agreements with Novartis Pharma; Bayer HealthCar and Eli Lilly.
Revenue TTM 25.4B
Net Income TTM 5.7B
EBITDA TTM 12.43B
Net Margin TTM 22.5%
Dividend yield 3.27%.
AMGN with nice setupHi Traders,
AMGN fell after Q2 Earnings back in August and entered a downtrend down to ~200 USD. With this, it entered a strong area of support (ATH of 2018, low of Oct. 2020).
AMGN then broke downward trend but then get capped by resistance at 210 USD and retestet downward trendline from above.
By the end of October just before earnings it started to move up with significant increase in volume. This weeks retest of supportlevel at 210 USD was perfectly in line with fib levels.
So by now the short term trend tends to be upwards, we have retestet trendline and support level and earnings behind us. Maybe ex-date can ruin this setup, but to be safe, an entry could also be done after passing last high at 219.26 USD. SL slighty under supportlevel of 210 USD.
First target is trendline and maybe ATH.
Cheers
Technical analysis (AMGN)Amgen, Inc. (AMGN)
Limit buy - 213,0$
Target - 243,05
Risk/Reward Ratio - 3,34
Stop-loss - 204,0
The price has approached a good level, we enter the position.
AMGEN who knows what they do, but it has to do with moneyInteresting compare to the crash off in money supply velocity to Amgen’s delayed bull run
Maybe something to do with their business model.
Also compares to money supply and seems to correlate with increase in money supply dollars finding their new homes as we can see as the money supply velocity drops off drastically.
AMGEN INC : CMP 206 AMGEN INC in Weekly Timeframe Correction from November 2019 l....this correction expected to end in 6 month....only buy after breakout which is above 230 on a weekly Closing basis....after Breakout Stock expected to run for target 400-485
AMGN: Short term sellAll trade in sell order/buy order, might not trigger, cancel if the price has run too far.
FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 AMGN: Amgen
2021-09-25 20:00:00
FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
